Repligen (RGEN) Director Karen A. Dawes Sells 20,000 Shares

Repligen (NASDAQ:RGEN) Director Karen A. Dawes sold 20,000 shares of Repligen stock in a transaction on Friday, May 11th. The stock was sold at an average price of $41.80, for a total value of $836,000.00. Following the sale, the director now owns 114,957 shares of the company’s stock, valued at $4,805,202.60. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

RGEN stock opened at $42.06 on Friday. The company has a quick ratio of 10.25, a current ratio of 12.22 and a debt-to-equity ratio of 0.17. The stock has a market capitalization of $1.83 billion, a P/E ratio of 60.96, a PEG ratio of 2.78 and a beta of 0.83. Repligen has a 1-year low of $41.65 and a 1-year high of $42.10.

Repligen (NASDAQ:RGEN) last released its quarterly earnings data on Tuesday, May 8th. The biotechnology company reported $0.17 earnings per share for the quarter, beating the consensus estimate of $0.15 by $0.02. The firm had revenue of $44.80 million during the quarter, compared to the consensus estimate of $43.88 million. Repligen had a return on equity of 6.06% and a net margin of 18.48%. The firm’s quarterly revenue was up 46.4% on a year-over-year basis. During the same period in the previous year, the company posted $0.15 earnings per share. sell-side analysts anticipate that Repligen will post 0.71 EPS for the current fiscal year.

RGEN has been the subject of several recent research reports. BidaskClub upgraded Repligen from a “hold” rating to a “buy” rating in a report on Monday. Zacks Investment Research upgraded Repligen from a “hold” rating to a “buy” rating and set a $42.00 price objective for the company in a report on Thursday, April 26th. Finally, TheStreet upgraded Repligen from a “c” rating to a “b-” rating in a report on Tuesday, March 13th. One research analyst has rated the stock with a hold rating and eight have issued a buy rating to the stock. The company currently has a consensus rating of “Buy” and a consensus target price of $44.25.

Hedge funds have recently added to or reduced their stakes in the stock. Swiss National Bank raised its holdings in shares of Repligen by 5.3% in the fourth quarter. Swiss National Bank now owns 63,700 shares of the biotechnology company’s stock valued at $2,311,000 after acquiring an additional 3,200 shares in the last quarter. Pier Capital LLC raised its holdings in Repligen by 12.3% in the fourth quarter. Pier Capital LLC now owns 166,195 shares of the biotechnology company’s stock worth $6,030,000 after purchasing an additional 18,256 shares in the last quarter. William Blair Investment Management LLC raised its holdings in Repligen by 70.1% in the fourth quarter. William Blair Investment Management LLC now owns 1,802,569 shares of the biotechnology company’s stock worth $65,397,000 after purchasing an additional 742,634 shares in the last quarter. State of Wisconsin Investment Board raised its holdings in Repligen by 45.0% in the fourth quarter. State of Wisconsin Investment Board now owns 37,700 shares of the biotechnology company’s stock worth $1,368,000 after purchasing an additional 11,700 shares in the last quarter. Finally, Arizona State Retirement System raised its holdings in Repligen by 224.2% in the fourth quarter. Arizona State Retirement System now owns 62,971 shares of the biotechnology company’s stock worth $2,285,000 after purchasing an additional 43,545 shares in the last quarter. Hedge funds and other institutional investors own 87.29% of the company’s stock.

Repligen Company Profile

Repligen Corporation, a bioprocessing company, focuses on the development, manufacture, and commercialization of products used to enhance the interconnected phases of the biological drug manufacturing process worldwide. It manufactures and supplies Protein A ligands to life sciences companies, which are the binding components of Protein A affinity resins for use in the downstream purification of monoclonal antibodies; and growth factor products used to supplement cell culture media to increase cell growth and productivity in a bioreactor.

Receive News & Ratings for Repligen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repligen and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply